4-甲基-5-乙酰基噻唑 | 38205-55-9

• 物质功能分类: 香精与香料 - 合成香料 - 内酯和含氧杂环化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲基-5-乙酰基噻唑
• 中文别名: 4-甲基-5-乙酰噻唑
• 英文名称: 1-(4-methyl-thiazol-5-yl)-ethanone
• 英文别名: 1-(4-methylthiazol-5-yl)ethanone；4-methyl-5-acetylthiazole；5-acetyl-4-methylthiazole；NLA-511；1-(4-Methyl-thiazol-5-yl)-aethanon；4-Methyl-5-acetyl-thiazol；1-(4-methyl-1,3-thiazol-5-yl)ethanone
• CAS: 38205-55-9
• 化学式: C₆H₇NOS
• mdl: MFCD09029046
• 分子量: 141.194
• InChiKey: MBLHLRLBSIWLMG-UHFFFAOYSA-N

物化性质

• 熔点：
  28-29 °C
• 沸点：
  107-108 °C(Press: 13 Torr)
• 密度：
  1.177±0.06 g/cm3(Predicted)
• LogP：
  0.350 (est)
• 保留指数：
  1134.5

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2934100090
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 危险性防范说明：
  P280,P305+P351+P338
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-(4-Methyl-1,3-Thiazol-5-Yl)Ethanone (May
Contain Up To 0.5 Eq Water)
: CBR01086
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 141,19 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-(4-Methyl-1,3-Thiazol-5-Yl)Ethanone (May Contain Up To 0.5 Eq Water)
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-(4-Methyl-1,3-Thiazol-5-Yl)Ethanone (May Contain Up To 0.5 Eq Water)
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
No data available
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - No data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-5-乙酰基噻唑 在 Almag CRED A₁₆₁ 、 NADP 、 glucose dehydrogenase 作用下， 以 水 、 二甲基亚砜 、 异丙醇 为溶剂， 35.0 ℃ 、50.0 kPa 条件下， 以47%的产率得到(R)-1-(4-methylthiazol-5-yl)ethanol
  参考文献：
  名称：

  Preparative access to medicinal chemistry related chiral alcohols using carbonyl reductase technology

  摘要：

  Libraries of highly enantioenriched secondary alcohols in both enantiomeric forms were synthesised by enzymatic reduction of their parent ketones using selectAZyme (TM) carbonyl reductase (CRED) technology. Commercially available CREDs were able to reduce a range of substrate classes efficiently and with very high enantioselectivity. Matching substrate classes to small subsets of CREDs enabled the fast development of preparative bioreductions and the rapid generation of 100-1500 mg samples of chiral alcohols in typically >95% ee and the majority in >= 99.0% ee. The conditions for small scale synthesis were then scaled up to 0.5 kg to deliver one of the chiral alcohols, (S)-1-(4-bromophenyl)-2-chloroethanol, in 99.8% ee and 91% isolated yield. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2013.09.015
• 作为产物：
  描述：

  乙酰丙酮 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 11.0h， 生成 4-甲基-5-乙酰基噻唑
  参考文献：
  名称：

  Design, synthesis and neuraminidase inhibitory activity of 4-methyl-5-(3-phenylacryloyl) thiazoles

  摘要：

  研究人员设计、合成了一系列基于查耳酮的 4-甲基-5-(3-苯基丙烯酰基)噻唑，并在体外评估了它们对流感神经氨酸酶（NA）的抑制活性。初步的结构-活性关系（SAR）分析表明，含酰胺的噻唑类化合物具有更强的效力。分析还表明，苯环 4 位上的单羟基比其他释放电子的基团或撤回电子的基团更有效。化合物 A2 和 A26 对 NA 更有效，IC50 值分别为 8.2 ± 0.5 μg/mL 和 6.2 ± 1.4 μg/mL。分子对接研究表明，噻唑骨架有利于NA的抑制活性。

  DOI：

  10.1007/s11030-023-10639-1

文献信息

• Thiazole derivatives and pharmaceutical composition comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04649146A1

  公开（公告）日：1987-03-10

  The invention relates to novel pharmaceutical compounds for treatment for ulcer of the formula: ##STR1## wherein R.sup.1 is lower alkyl, carboxy, hydroxymethyl, halomethyl, lower alkylthiomethyl or hydroxyiminomethyl, R.sup.2 is hydrogen, hydroxy, lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino or guanidino optionally substituted with dimethylaminomethylene, R.sup.3 is dihydroisoquinolyl which may be substituted with halogen, lower alkyl, lower alkoxy, carboxy, hydroxy, pyridyl, amino, lower alkylamino, pyridylamino or guanidino, Q is --CO--, and n is an integer of 0 or 1, and pharmaceutically acceptable salts thereof.

  该发明涉及一种用于治疗溃疡的新型药物化合物，其化学式为：##STR1## 其中R.sup.1为较低的烷基、羧基、羟甲基、卤代甲基、较低的烷基硫甲基或羟基亚甲基，R.sup.2为氢、羟基、较低的烷基、吡啶基、氨基、较低的烷基氨基、吡啶基氨基或胍基，可选择地取代二甲氨基亚甲基，R.sup.3为二氢异喹啉基，可取代卤素、较低的烷基、较低的烷氧基、羧基、羟基、吡啶基、氨基、较低的烷基氨基、吡啶基氨基或胍基，Q为--CO--，n为0或1，以及其药学上可接受的盐。
• Pyrimidinone Derivatives as Antimalarial Agents
  申请人：SANOFI

  公开号：US20150183804A1

  公开（公告）日：2015-07-02

  The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R 2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

  这项发明涉及一种新型的嘧啶酮基杂环化合物，这些化合物是寄生虫生长抑制剂，其一般式为（I），其中Y是从三种桥联吗啉中选择的吗啉，L是键或连接物，n=0或1，当n=0时R2是甲基基团，当n=1时是氢原子。其制备方法和治疗用途。
• 1-heteroazolyl-1-heterocyclyl alkane derivatives and their use and their
  申请人：Astra Aktiebolag

  公开号：US05607956A1

  公开（公告）日：1997-03-04

  The present invention relates to novel heterocyclic compounds having the general formula (1) ##STR1## geometric and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof; having therapeutic activity, processes and intermediates for their preparation, pharmaceutical formulations containing said compounds and the medicinal use of said compounds.

  本发明涉及具有一般式（1）##STR1##的新异环化合物，其中存在几何和光学异构体以及其外消旋体，以及其药学上可接受的酸盐和溶剂化合物；具有治疗活性，用于其制备的过程和中间体，含有所述化合物的药物制剂以及所述化合物的药用。
• 5-(3-苯基丙烯酰基)噻唑衍生物及其制备方 法与应用
  申请人：湖南大学

  公开号：CN108546254B

  公开（公告）日：2020-11-24

  本发明涉及式Ⅰ所示5‑(3‑苯基丙烯酰基)噻唑衍生物及其药学上可接受的盐，药物组合物以及其在制备流感病毒神经氨酸酶抑制剂中的应用。其中，R选自：甲基、乙基、C3～C4直链或C3～C4支链烷基；R1选自：氢、2‑硝基、3‑硝基、4‑硝基、2‑氨基、3‑氨基、4‑氨基、2‑甲氨基、3‑甲氨基、4‑甲氨基、2‑二甲氨基、3‑二甲氨基、4‑二甲氨基、2‑甲氧基、3‑甲氧基、4‑甲氧基、2‑乙氧基、3‑乙氧基、4‑乙氧基、2‑羟基、3‑羟基、4‑羟基、2,3‑二羟基、2,4‑二羟基、2,5‑二羟基、3,4‑二羟基、3,5‑二羟基、2‑羟基‑3‑甲氧基、3‑羟基‑4‑甲氧基、4‑羟基‑3‑甲氧基、4‑羟基‑3‑乙氧基、3,4,5‑三甲氧基或4‑羟基‑3,5‑二甲氧基；R2选自：氢、C1～C2烷基、C3～C4直链或C3～C4支链烷基、三氟甲基或氯代C1～C4直链烷基。
• Thiazole derivatives, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04735957A1

  公开（公告）日：1988-04-05

  New thiazole derivatives of the formula: ##STR1## wherein R.sup.1 is lower alkyl, carboxy, a drivative of carboxy, hydroxymethyl, halomethyl, lower alkylthiomethyl, hydroxyiminomethyl or alkenyl which may be substituted with lower alkoxycarbonyl, pyridyl or cyano, R.sup.2 is hydrogen, hydroxy, lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkylN-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower)alkylamino optionally substituted with lower alkoxy, R.sup.3 is lower alkyl, halo(lower)alkyl or N-containing unsaturated heterocyclic group which may be substituted with halogen, lower alkyl, lower alkoxy, carboxy, a derivative of carboxy, hydroxy, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino, N-oxide or ar(lower)alkylamino optionally substituted with lower alkoxy, Q is --CO--, and n is an integer of 0 or 1, provided that when both of R.sup.1 and R.sup.3 are lower alkyl then n is an integer of 1 and R.sup.2 is lower alkyl, pyridyl, amino, lower alkylamino, pyridylamino, arylamino, acylamino, N-(lower)alkyl-N-acylamino, guanidino optionally substituted with dimethylaminomethylene, or ar(lower)alkylamino optionally substituted with lower alkoxy, and when R.sup.1 is lower alkyl and R.sup.3 is halo(lower)alkyl then n is an integer of 1, and pharmaceutically acceptable salts thereof, and processes for preparation thereof and pharmaceutical composition comprising the same. These derivatives and pharmaceutically acceptable salts thereof are useful as cardiotonic agents and anti-ulcer agents.

  新的噻唑衍生物的化学式为：##STR1## 其中R.sup.1是较低的烷基，羧基，羧基衍生物，羟甲基，卤代甲基，较低的烷基硫甲基，羟基亚胺甲基或烯基，该烯基可以用较低的烷氧羰基，吡啶基或氰基取代，R.sup.2为氢，羟基，较低的烷基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基N-酰基氨基，瓜二氨基可选地用二甲氨基甲基取代，或者是可选地用较低的烷氧基取代的ar(较低)烷基氨基，R.sup.3是较低的烷基，卤代(较低)烷基或含氮的不饱和杂环基，该基可以用卤代，较低的烷基，较低的烷氧基，羧基，羧基衍生物，羟基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基-N-酰基氨基，瓜二氨基，N-氧化物或可选地用较低的烷氧基取代的ar(较低)烷基氨基取代，Q为--CO--，n为0或1的整数，但当R.sup.1和R.sup.3都是较低的烷基时，n为1的整数，而R.sup.2为较低的烷基，吡啶基，氨基，较低的烷基氨基，吡啶基氨基，芳基氨基，酰基氨基，N-(较低)烷基-N-酰基氨基，瓜二氨基可选地用二甲氨基甲基取代，或者是可选地用较低的烷氧基取代的ar(较低)烷基氨基，而当R.sup.1为较低的烷基且R.sup.3为卤代(较低)烷基时，n为1的整数，以及其药学上可接受的盐，以及其制备方法和包含其的制药组合物。这些衍生物及其药学上可接受的盐可用作心力衰竭药物和抗溃疡药物。